- Abbott, Teva, Takeda are also said to have looked at Rimsa
- Mexican maker of generic drugs could fetch about $1 billion
Mexican generic-drug company Representaciones e Investigaciones Medicas SA is attracting takeover interest from Sanofi, Pfizer Inc. and Abbott Laboratories, people with knowledge of the matter said.
The Mexico City-based drugmaker, known as Rimsa, also has drawn inquiries from Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Co., said the people, who asked not to be identified because the information is private. Goldman Sachs Group Inc. is managing the sale, in which the company may fetch about $1 billion, the people said.
Foreign companies and investors have been pursuing transactions in Mexico’s fragmented generic-drug industry. They are seeking to gain exposure to a market where relatively low rates of health-care spending are projected to rise to converge with other emerging markets, including Brazil and Chile. Last year, Endo International Plc bought Mexico City-based Grupo Farmaceutico Somar, while private-equity firm General Atlantic LLC acquired a minority stake in Laboratorios Sanfer.
Rimsa didn’t respond to calls and e-mails seeking comment. Spokesmen for Goldman Sachs and Israel-based Teva declined to comment. Representatives for Paris-based Sanofi, New York-based Pfizer, Abbott Park, Illinois-based Abbott and Osaka, Japan-based Takeda didn’t respond to requests for comment.
The Rimsa sale process was reported July 6 by Alberto Aguilar in a column that appears in El Universal.
Dario Celis, whose column appears in newspaper Excelsior, wrote Sept. 10 that there’s one offer that’s being closely analyzed, without saying who made it. He said speculation pointed to “U.S. big pharma,” while others thought it could be Takeda.